|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Schering-Plough: PharmaVitae Profile 2005 |
|
|
|
|
€ 4 845,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Décembre 2005 |
Taille du document : |
151 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The UK piling Market
40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded |
365,00 €
|
| |
| |
Healthcare In Southern Ireland
40 pages | Mai 2000 |
The Republic Of Ireland Presentation Includes:- The Structure Of The Health Service In The Republic Of Ireland- Capital Expenditure On Health Care In The Republic Of Ireland- Number Of Publicly Funded |
327,00 €
|
| |
| |
The Pharmaceutical Distribution Outlook 1998-2008
165 pages | Octobre 1998 |
Industry growth and consolidation means that pharmaceutical manufacturers are no longer geographically limited in their operations and now market their products globally, creating a vast commercia |
795,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Healthcare In Wales
50 pages | Mai 2000 |
The Welsh Presentation Includes:- The Structure Of The NHS In Wales- Revenue Expenditure On Health Services In Wales- Number Of Hospital Units - Number Of Available Inpatient Beds- Number Of Occupied |
327,00 €
|
| |
| |
Healthcare: Germany
106 pages | Octobre 2000 |
Compare the changes in expenditure between the different healthcare sectors in Germany · Understand the main factors affecting demand for healthcare services in Germany · Examine the |
578,54 €
|
| |
| |
The CNS Outlook 2000
203 pages | Octobre 2000 |
The Central Nervous System (CNS) market has shown sustained growth in 1999 with the expansion continuing to be driven by several factors.A greater understanding of the neuropharmacological mechanisms |
955,00 €
|
| |
| |
Pharmaceutical Pricing Strategies
121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
The Japanese Pharmaceutical Market Outlook 2001
142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies.
Now, however, extensive cultur |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Schering-Plough: PharmaVitae Profile 2005 |
|
|
Introduction
This analysis examines the current position and future outlook for Schering-Plough in the ethical pharmaceutical sector. The profile encompasses global strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector
Understand how Schering-Plough ethical sales are set to grow at a 2004-2010 CAGR of 7.4%, driven by Remicade, Zetia/Vytorin and the Intron franchise
|
|
Introduction
This analysis examines the current position and future outlook for Schering-Plough in the ethical pharmaceutical sector. The profile encompasses global strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark Schering-Plough's performance against key rivals in the ethical pharmaceutical sector
Understand how Schering-Plough ethical sales are set to grow at a 2004-2010 CAGR of 7.4%, driven by Remicade, Zetia/Vytorin and the Intron franchise
|
|
|
PPLSEN
|
|
|
|
|
